Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / BASIC RESEARCH
CXCR4/CXCR7 gene-silencing suppresses ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and activation of MAPK signalling pathway
1
Department of Pathology, Chengdu Fifth People’s Hospital, Chengdu, Sichuan, China
2
Department of Pathology, The Fifth Affiliated People’s Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
Submission date: 2020-04-29
Final revision date: 2020-08-07
Acceptance date: 2020-08-18
Online publication date: 2020-11-05
Publication date: 2026-07-03
Corresponding author
Arch Med Sci 2026;22(3):1774-1786
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Ovarian cancer is the most common malignant cancer among females. This study aimed to investigate role of the CXCL12-CXCR4/CXCR7 chemokine axis in ovarian cancer.
Material and methods:
SKOV3 cells were transfected with siCXCR4/siCXCR7 plasmids and divided into SKOV3, LV3, LV3-siCXCR4, and LV3-siCXCR7 groups. Cell viability and apoptosis were examined using MTT and flow cytometry. ELISA was conducted to evaluate vascular-endothelial growth factor-A (VEGF-A), interleukin-6 (IL-6), and interleukin-8 (IL-8) levels. SKOV3 cells were transplanted into mice to establish a Xenograft model. The tumour volume of the Xenograft model was recorded. CD31, matrix-metalloprotein-9 (MMP-9), vimentin, and E-cadherin expressions in SKOV3 cells and tumour tissues were evaluated with quantitative real-time PCR (qRT-PCR) and western blot. Immunohistochemistry assay was used to detect VEGF-A, CD31, MMP-9, vimentin, and E-cadherin expression.
Results:
SKOV3 cells strongly expressed CXCR4 and CXCR7. CXCL12 significantly enhanced cell viability, and CXCR4/CXCR7 inhibitor remarkably reduced cell viability of SKOV3 (p < 0.05). CXCR4/CXCR7 gene-silencing significantly decreased SKOV3 viability compared to the SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing modulated cell cycle and increased apoptosis rates compared to SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing inhibited VEGF-1, IL-6, and IL-8 secretion. CXCR4/CXCR7 gene-silencing modulated levels of CD31, MMP-9, vimentin, and E-cadherin. CXCR4/CXCR7 gene-silencing suppressed p-ERK1/2 (p < 0.05) and strengthened inhibitive effects of CXCR4/CXCR7 inhibitor on p-ERK1/2. CXCR4/CXCR7 gene-silencing reduced tumour volume and regulated tumourigenesis-associated molecules in the mouse Xenograft model.
Conclusions:
CXCR4/CXCR7 gene-silencing could suppress ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and mitogen-activated protein kinase (MAPK) signalling pathway.
Ovarian cancer is the most common malignant cancer among females. This study aimed to investigate role of the CXCL12-CXCR4/CXCR7 chemokine axis in ovarian cancer.
Material and methods:
SKOV3 cells were transfected with siCXCR4/siCXCR7 plasmids and divided into SKOV3, LV3, LV3-siCXCR4, and LV3-siCXCR7 groups. Cell viability and apoptosis were examined using MTT and flow cytometry. ELISA was conducted to evaluate vascular-endothelial growth factor-A (VEGF-A), interleukin-6 (IL-6), and interleukin-8 (IL-8) levels. SKOV3 cells were transplanted into mice to establish a Xenograft model. The tumour volume of the Xenograft model was recorded. CD31, matrix-metalloprotein-9 (MMP-9), vimentin, and E-cadherin expressions in SKOV3 cells and tumour tissues were evaluated with quantitative real-time PCR (qRT-PCR) and western blot. Immunohistochemistry assay was used to detect VEGF-A, CD31, MMP-9, vimentin, and E-cadherin expression.
Results:
SKOV3 cells strongly expressed CXCR4 and CXCR7. CXCL12 significantly enhanced cell viability, and CXCR4/CXCR7 inhibitor remarkably reduced cell viability of SKOV3 (p < 0.05). CXCR4/CXCR7 gene-silencing significantly decreased SKOV3 viability compared to the SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing modulated cell cycle and increased apoptosis rates compared to SKOV3 or LV3 group (p < 0.05). CXCR4/CXCR7 gene-silencing inhibited VEGF-1, IL-6, and IL-8 secretion. CXCR4/CXCR7 gene-silencing modulated levels of CD31, MMP-9, vimentin, and E-cadherin. CXCR4/CXCR7 gene-silencing suppressed p-ERK1/2 (p < 0.05) and strengthened inhibitive effects of CXCR4/CXCR7 inhibitor on p-ERK1/2. CXCR4/CXCR7 gene-silencing reduced tumour volume and regulated tumourigenesis-associated molecules in the mouse Xenograft model.
Conclusions:
CXCR4/CXCR7 gene-silencing could suppress ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and mitogen-activated protein kinase (MAPK) signalling pathway.
REFERENCES (35)
1.
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68: 284-96.
2.
Zhihong Z, Ruibin C, Liping L, et al. MicroRNA-1179 regulates proliferation and chemosensitivity of human ovarian cancer cells by targeting the PTEN-mediated PI3K/AKT signaling pathway. Arch Med Sci 2019; 16: 907-14.
3.
Buranjiang G, Kuerban R, Abuduwanke, et al. MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Arch Med Sci 2019; 15: 1520-9.
4.
Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi24-32.
5.
Chien J, Poole EM. Ovarian cancer prevention, screening, and early detection: report from the 11th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer 2017; 27: S20-2.
6.
Chen Y, Du H. The promising PARP inhibitors in ovarian cancer therapy: from olaparib to others. Biomed Pharmacother 2018; 99: 552-60.
7.
Zheng N, Liu W, Chen J, et al. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. Mol Carcinog 2019; 58: 144-55.
8.
Werner TA, Forster CM, Dizdar L, et al. CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. Br J Cancer 2017; 117: 1837-45.
9.
Grundker C, Bauerschmitz G, Knapp J, et al. Inhibition of SDF-1/CXCR4-induced epithelial-mesenchymal transition by kisspeptin-10. Breast Cancer Res Treat 2015; 152: 41-50.
10.
Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283-94.
11.
Hattermann K, Held-Feindt J, Lucius R, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Can Res 2010; 70: 3299-308.
12.
Miao Z, Luker KE, Summers BC, et al. CXCR7 (RD C1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104: 15735-40.
13.
Hattermann K, Mentlein R. An infernal trio: the chemokine CXCL12 and its receptor CXCR4 and CXCR7 in tumor biology. Ann Anat 2013; 195: 103-10.
14.
Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-20.
15.
Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292: C987-95.
16.
Yin Q, Jin P, Liu X, et al. SDF-1 alpha inhibits hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells through PI3K/Akt and ERK1/2 signaling pathways. Mol Biol Rep 2011: 38: 9-16.
17.
Zhang L, Wang Y, Ma J, et al. Exogenous MSCs ameliorate hypoxia/reoxygenation injury in renal tubular epithelial cells through JAK/STAT signaling pathway-mediated regulation of HMGB1. Am J Transl Res 2017; 9: 2412-20.
18.
Li S, Dong P, Wang J, et al. Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Lett 2010; 298: 222-30.
19.
Bao R, Shu Y, Wu X, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 2014; 14: 217.
20.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ct method. Methods 2001; 25: 402-8.
21.
Gao Y, Zhao XL, Gu Q, et al. Correlation of vasculogenic mimicy with clinicopathologic features and prognosis of ovarian carcinoma. Zhonghua Bing Li Xue Za Zhi 2009; 38: 585-9.
22.
Xu H, Zhao H, Yu J. HOXB5 promotes retinoblastoma cell migration and invasion via ERK1/2 pathway-mediated MMPs production. Am J Transl Res 2018; 10: 1703-12.
23.
Oberaigner W, Minicozzi P, Bielska-Lasota M, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 2012; 51: 441-53.
24.
Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am 2014; 43: 423-42.
25.
Yuan C, Liu X, Li R, et al. Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk. Arch Med Sci 2020; 16: 682-91.
26.
Mao TL, Fan KF, Liu CL. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Gene Ther 2017; 24: 621-9.
27.
Khare P, Bose A, Singh P, et al. Gonadotropin and tumorigenesis: direct and indirect effects on inflammatory and immunosuppressive mediators and invasion. Mol Carcinog 2017; 56: 359-70.
28.
Zhang Y, Li Y, Li H, et al. Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model. Biomed Pharmacother 2018; 101: 391-8.
29.
Zhang LQ, Lv RW, Qu XD, et al. Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the inhibition of the MAPK signaling pathway. Anal Cell Pathol 2017; 2017: 8158254.
30.
Wagner EF, Nebreda AR. Signal integration by JNK and MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
31.
Islam M, Sharma S, Teknos TN. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS One 2014; 9: e88527.
32.
Islam M, Lin G, Brenner JC, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res 2009; 7: 1771-80.
33.
Katsura M, Shoji F, Okamoto T, et al. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients. Cancer Sci 2018; 109: 154-65.
34.
Xu D, Li R, Wu J, et al. Drug design targeting the CXCR4/CXCR7/CXCL12 pathway. Curr Top Med Chem 2016; 16: 1441-51.
35.
Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis 2014; 5: e1488.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
